Study on the mechanism causing elevation of serum CA19-9 levels in diabetic patients

Jun Murai, Sumiko Soga, Hiroshi Saito, Michio Otsuki, Takatoshi Kitada, Yoshifumi Saisho, Hideji Nakamura, Soji Kasayama, Masafumi Koga

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Serum CA19-9 levels are often elevated in diabetic patients. To elucidate this mechanism, we investigated the metabolism of CA19-9 in diabetic patients without obvious cancer. Study 1 included 119 patients in whom HbA1c, glycated albumin (GA) and CA19-9 were measured at the time of hospital admission. Study 2 examined 6 patients with markedly elevated CA19-9 levels (≥100 U/mL). Their half-lives for HbA1c, GA, and serum CA19-9 were calculated using the data before and after diabetes treatment. Three diabetic patients with pancreatic cancer were also examined as controls. In Study 1, serum CA19-9 (logarithmically transformed value) was significantly correlated with fasting plasma glucose (FPG), HbA1c and GA. On multivariate analysis, GA and FPG, but not HbA1c, were significant explanatory variables for serum CA19-9. In Study 2, serum CA19-9 decreased together with HbA1c and GA after diabetes treatment. The calculated half-lives for HbA1c, GA, and serum CA19-9 were 33.8 days, 16.1 days, and 10.9 days, respectively. The half-life of serum CA19-9 was longer in the study patients than that reported in patients with malignant tumors. By contrast, in the diabetic patients with pancreatic cancer serum CA19-9 showed a marginal decrease after diabetes treatment. Taken all together, prolonged half-life of serum CA19-9 may contribute to the increase in serum CA19-9 levels in diabetic patients without obvious cancer.

Original languageEnglish
Pages (from-to)885-891
Number of pages7
JournalEndocrine Journal
Volume60
Issue number7
DOIs
Publication statusPublished - 2013

Fingerprint

Serum
Pancreatic Neoplasms
Half-Life
Fasting
Glucose
Neoplasms
Serum Albumin
glycosylated serum albumin
Therapeutics
Multivariate Analysis

Keywords

  • CA19-9
  • Diabetes
  • Glycated albumin
  • HbA1c

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Study on the mechanism causing elevation of serum CA19-9 levels in diabetic patients. / Murai, Jun; Soga, Sumiko; Saito, Hiroshi; Otsuki, Michio; Kitada, Takatoshi; Saisho, Yoshifumi; Nakamura, Hideji; Kasayama, Soji; Koga, Masafumi.

In: Endocrine Journal, Vol. 60, No. 7, 2013, p. 885-891.

Research output: Contribution to journalArticle

Murai, J, Soga, S, Saito, H, Otsuki, M, Kitada, T, Saisho, Y, Nakamura, H, Kasayama, S & Koga, M 2013, 'Study on the mechanism causing elevation of serum CA19-9 levels in diabetic patients', Endocrine Journal, vol. 60, no. 7, pp. 885-891. https://doi.org/10.1507/endocrj.EJ12-0364
Murai, Jun ; Soga, Sumiko ; Saito, Hiroshi ; Otsuki, Michio ; Kitada, Takatoshi ; Saisho, Yoshifumi ; Nakamura, Hideji ; Kasayama, Soji ; Koga, Masafumi. / Study on the mechanism causing elevation of serum CA19-9 levels in diabetic patients. In: Endocrine Journal. 2013 ; Vol. 60, No. 7. pp. 885-891.
@article{29a377e256654cc8a88e788263434947,
title = "Study on the mechanism causing elevation of serum CA19-9 levels in diabetic patients",
abstract = "Serum CA19-9 levels are often elevated in diabetic patients. To elucidate this mechanism, we investigated the metabolism of CA19-9 in diabetic patients without obvious cancer. Study 1 included 119 patients in whom HbA1c, glycated albumin (GA) and CA19-9 were measured at the time of hospital admission. Study 2 examined 6 patients with markedly elevated CA19-9 levels (≥100 U/mL). Their half-lives for HbA1c, GA, and serum CA19-9 were calculated using the data before and after diabetes treatment. Three diabetic patients with pancreatic cancer were also examined as controls. In Study 1, serum CA19-9 (logarithmically transformed value) was significantly correlated with fasting plasma glucose (FPG), HbA1c and GA. On multivariate analysis, GA and FPG, but not HbA1c, were significant explanatory variables for serum CA19-9. In Study 2, serum CA19-9 decreased together with HbA1c and GA after diabetes treatment. The calculated half-lives for HbA1c, GA, and serum CA19-9 were 33.8 days, 16.1 days, and 10.9 days, respectively. The half-life of serum CA19-9 was longer in the study patients than that reported in patients with malignant tumors. By contrast, in the diabetic patients with pancreatic cancer serum CA19-9 showed a marginal decrease after diabetes treatment. Taken all together, prolonged half-life of serum CA19-9 may contribute to the increase in serum CA19-9 levels in diabetic patients without obvious cancer.",
keywords = "CA19-9, Diabetes, Glycated albumin, HbA1c",
author = "Jun Murai and Sumiko Soga and Hiroshi Saito and Michio Otsuki and Takatoshi Kitada and Yoshifumi Saisho and Hideji Nakamura and Soji Kasayama and Masafumi Koga",
year = "2013",
doi = "10.1507/endocrj.EJ12-0364",
language = "English",
volume = "60",
pages = "885--891",
journal = "Endocrine Journal",
issn = "0918-8959",
publisher = "Japan Endocrine Society",
number = "7",

}

TY - JOUR

T1 - Study on the mechanism causing elevation of serum CA19-9 levels in diabetic patients

AU - Murai, Jun

AU - Soga, Sumiko

AU - Saito, Hiroshi

AU - Otsuki, Michio

AU - Kitada, Takatoshi

AU - Saisho, Yoshifumi

AU - Nakamura, Hideji

AU - Kasayama, Soji

AU - Koga, Masafumi

PY - 2013

Y1 - 2013

N2 - Serum CA19-9 levels are often elevated in diabetic patients. To elucidate this mechanism, we investigated the metabolism of CA19-9 in diabetic patients without obvious cancer. Study 1 included 119 patients in whom HbA1c, glycated albumin (GA) and CA19-9 were measured at the time of hospital admission. Study 2 examined 6 patients with markedly elevated CA19-9 levels (≥100 U/mL). Their half-lives for HbA1c, GA, and serum CA19-9 were calculated using the data before and after diabetes treatment. Three diabetic patients with pancreatic cancer were also examined as controls. In Study 1, serum CA19-9 (logarithmically transformed value) was significantly correlated with fasting plasma glucose (FPG), HbA1c and GA. On multivariate analysis, GA and FPG, but not HbA1c, were significant explanatory variables for serum CA19-9. In Study 2, serum CA19-9 decreased together with HbA1c and GA after diabetes treatment. The calculated half-lives for HbA1c, GA, and serum CA19-9 were 33.8 days, 16.1 days, and 10.9 days, respectively. The half-life of serum CA19-9 was longer in the study patients than that reported in patients with malignant tumors. By contrast, in the diabetic patients with pancreatic cancer serum CA19-9 showed a marginal decrease after diabetes treatment. Taken all together, prolonged half-life of serum CA19-9 may contribute to the increase in serum CA19-9 levels in diabetic patients without obvious cancer.

AB - Serum CA19-9 levels are often elevated in diabetic patients. To elucidate this mechanism, we investigated the metabolism of CA19-9 in diabetic patients without obvious cancer. Study 1 included 119 patients in whom HbA1c, glycated albumin (GA) and CA19-9 were measured at the time of hospital admission. Study 2 examined 6 patients with markedly elevated CA19-9 levels (≥100 U/mL). Their half-lives for HbA1c, GA, and serum CA19-9 were calculated using the data before and after diabetes treatment. Three diabetic patients with pancreatic cancer were also examined as controls. In Study 1, serum CA19-9 (logarithmically transformed value) was significantly correlated with fasting plasma glucose (FPG), HbA1c and GA. On multivariate analysis, GA and FPG, but not HbA1c, were significant explanatory variables for serum CA19-9. In Study 2, serum CA19-9 decreased together with HbA1c and GA after diabetes treatment. The calculated half-lives for HbA1c, GA, and serum CA19-9 were 33.8 days, 16.1 days, and 10.9 days, respectively. The half-life of serum CA19-9 was longer in the study patients than that reported in patients with malignant tumors. By contrast, in the diabetic patients with pancreatic cancer serum CA19-9 showed a marginal decrease after diabetes treatment. Taken all together, prolonged half-life of serum CA19-9 may contribute to the increase in serum CA19-9 levels in diabetic patients without obvious cancer.

KW - CA19-9

KW - Diabetes

KW - Glycated albumin

KW - HbA1c

UR - http://www.scopus.com/inward/record.url?scp=84880934328&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880934328&partnerID=8YFLogxK

U2 - 10.1507/endocrj.EJ12-0364

DO - 10.1507/endocrj.EJ12-0364

M3 - Article

C2 - 23708182

AN - SCOPUS:84880934328

VL - 60

SP - 885

EP - 891

JO - Endocrine Journal

JF - Endocrine Journal

SN - 0918-8959

IS - 7

ER -